Clinical trial · Interventional
Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer
Bevacizumab and Carboplatin/Paclitaxel and Radiation in Stage III Non-Small Cell Lung Cancer
NCT00578149CI-TRIAL-00001042completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to learn what effects (good and bad) bevacizumab in conjunction with carboplatin/paclitaxel and radiation therapy has on patients with non-small cell lung cancer (NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To examine the time to progression of the novel regimen in stage III patients treated with concurrent chemoradiotherapy.
Secondary outcomes (1)
- measure
- Response rate, overall survival, and patterns of failure and toxicity of the novel therapy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed non-small cell lung cancer (NSCLC) that have been evaluated and determined not to be candidates for surgical resection as part of their definitive management of stage III disease. * Age 18 years or older * ECOG performance status of 0-1 * Life Expectancy of greater than six months * Normal organ and marrow function * Women and men of child-bearing potential must agree to use adequate contraception Exclusion Criteria: * Prior chemotherapy or thoracic radiation therapy * Squamous histology or any histology in close proximity to a major vessel * Active hemoptysis * History of hypercoagulability * Known distant metastatic disease * History of allergic reactions attributed to compounds with similar chemical or biological composition to bevacizumab, carboplatin, paclitaxel or other agents used in this study * Patients with uncontrolled intercurrent illness * Pregnant women * Major surgical procedure, open biopsy, or significant traumatic injury with in 28 days prior to day 0 * Minor surgical procedure within 7 days to day 0 * HIV-positive patients receiving combination anti-retroviral therapy. * Non-skin cancer malignancy in the past 5 years.
References
Publications (0)
Data not yet available
No reference posted for this study.